Why the study?
Does SLV306 reduce proteinuria and urinary albumin excretion in rats with streptozotocin-induced diabetes?
Does SLV306 reduce proteinuria and urinary albumin excretion in rats with streptozotocin-induced diabetes?
SLV306, a dual inhibitor of neutral endopeptidase and endothelin-converting enzyme, reduces proteinuria, albuminuria, and renal matrix protein content in diabetic rats independently of blood pressure, with effects comparable to ACE inhibition.
No takes yet. Share an insight, caveat, or question.
May support dual NEP/ECE inhibition for diabetic proteinuria in models; leaves open translation to human disease.
ne-Reinke et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: